English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 米国の過活動膀胱市場
カテゴリ
医薬品 (4962)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1523)
糖尿病 (192)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

米国の過活動膀胱市場

U.S. Overactive Bladder Market

発行 Frost & Sullivan
出版日 2009年11月 商品コード 103524
ページ情報 英文 83 Pages
価格
US$ 6,000 換算 ¥ 482,820 (税抜) Web Access (Regional License)
US$ 6,500 換算 ¥ 523,055 (税抜) Hard Copy & Web Access (Regional License)


原文目次

Abstract

This research service covers the U.S. overactive bladder market from 2005-2015. Included is a disease overview, product analysis, total market revenue forecasts, product revenue forecasts, patient forecasts and market share analysis. The market is segmented by product: Detrol, Detrol LA, Ditropan, Ditropan XL, Enablex, Oxytrol, Sanctura, Sanctura XR, VESIcare, and others. Major market challenges, drivers, and restraints and identified and discussed as well as pipeline by phase.

Table of Contents

1. Executive Summary

U.S. Overactive Bladder Market

  • Introduction

2. Market Introduction

Research Scope and Methodology

  • Scope and Segmentation
  • Research Methodology

Market Overview

  • Market Engineering Measurements
  • Disease Overview
  • Treatment Options
  • Patient Forecasts
  • Industry Challenges
  • Market Drivers
  • Market Restraints

Product Analysis

  • Product Analysis
  • Product Comparisons
  • Recently Approved Products

Pipeline Analysis

  • Phase III
  • Phase II
  • Phase I

3. Competitive Analysis

Overview

  • Competitive Structure

Forecasts and Trends

  • Total Market
  • Revenue Forecasts by Product

Market Share Analysis

  • Company Market Share
  • Product Market Share
  • Drug Delivery Market Share

4. Appendix

Decision Support Databases

  • Population 65 Plus
  • Female Population 65 Plus
  • Male Population 65 Plus
  • Total Life Expectancy at Birth
  • Birth Rate
Back to Top